The stock of Bio-Rad Laboratories Inc. (NYSE:BIO) last traded at $288.99, down -2.29% from the previous session.
BIO stock price is now 0.13% away from the 50-day moving average and -9.08% away from the 200-day moving average. The market capitalization of the company currently stands at $8.24B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On April 03, 2024, Citigroup Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $400 to quote $365, while ‘UBS’ rates the stock as ‘Buy’
In other news, Crowley Michael, EVP, GBL Commercial Operations sold 369 shares of the company’s stock on Jun 13 ’24. The stock was sold for $104,023 at an average price of $281.91. Upon completion of the transaction, the EVP, GBL Commercial Operations now directly owns 6,573 shares in the company, valued at $1.9 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 28 ’24, EVP, General Counsel & Sec ERNST TIMOTHY S sold 2,500 shares of the business’s stock. A total of $826,375 was realized by selling the stock at an average price of $330.55. This leaves the insider owning 3,397 shares of the company worth $0.98 million. A total of 30.94% of the company’s stock is owned by insiders.
During the past 12 months, Bio-Rad Laboratories Inc. has had a low of $261.59 and a high of $431.79. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 6.57, and a quick ratio of 4.89. The fifty day moving average price for BIO is $287.863 and a two-hundred day moving average price translates $317.2833 for the stock.
The latest earnings results from Bio-Rad Laboratories Inc. (NYSE: BIO) was released for 2024-03-31. The net profit margin was -12.37% and return on equity was -3.43% for BIO. The company reported revenue of $610.82 million for the quarter, compared to $676.84 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -9.75 percent.
